Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.